Please login to the form below

Aimmune

This page shows the latest Aimmune news and features for those working in and with pharma, biotech and healthcare.

Aimmune gets FDA panel backing for peanut allergy therapy

Step closer to becoming first approved treatment. Aimmune’s AR101 has moved a step closer to becoming the first approved peanut allergy treatment in the US after an FDA advisory committee ... Aimmune has also been filed for approval in Europe, with a

Latest news

DBV refiles peanut allergy immunotherapy in the US

four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... Aimmune is expecting an approval decision on AR101 by January 2020, and the FDA has planned an advisory committee
Aimmune wins over ICER for peanut allergy product

Analysts predict blockbuster status for first-in-class. Aimmune is still a few months away from a potential US approval of its peanut allergy drug AR-101, but already has a ... derailed. Meanwhile, Aimmune also seems to be in the lead in Europe, with a
Aimmune preps EU filing for peanut allergy immunotherapy

Company set to be first to market. US biotech Aimmune has a positive European phase 3 study for its peanut allergy therapy AR101 to match its US trial, setting up an ... Subjects in the study were given escalating doses of AR101 over six months to induce
FDA moves into crisis mode as shutdown drags on

One company – Aimmune Therapeutics – has already said it has been notified that as a direct result of the shutdown, the FDA will not commence review of its marketing application for peanut
VCCP Health lands record haul at the PM Society Awards

Craft Award for Disease Awareness (HCPs) - Solaris Health &Watchable for Aimmune.

More from news
Approximately 5 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Integrating patient reported outcomes into clinical trials

Aimmune Therapeutics prepared for commercialisation by using two PRO scales to show the effect of its peanut allergy drug on people’s emotions and social lives.
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy. ... However, Aimmune reported in February 2019 that the FDA had initially determined that the drug, as an allergenic extract, was exempt from the
Drug launches to watch in 2019

Now a US biotech company, Aimmune, looks set to bring the first treatment to market by the end of this year. ... Aimmune Therapeutics submitted the drug to the FDA on 21 December.
Deal Watch November 2016

licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Consultant: competitive salary

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Vice President: Competitive Salary Offered

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Subscribe to our email news alerts

PMHub

Add my company

Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat: A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product: In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team: Enhanced expertise to deliver impactful internal training programmes for healthcare clients...